Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015

Date: December 23, 2015
Pages: 700
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CA2E7560486EN
Leaflet:

Download PDF Leaflet

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015’, provides an overview of the Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Drug Profiles
Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2015
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corporation, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprogen, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioInvent International AB, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis S.A., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by CTI BioPharma Corp., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hospira, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics S.A., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Limited, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lead Discovery Center GmbH, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MediGene AG, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech, LLC, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co., Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mirna Therapeutics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Molecular Templates Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Limited, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Theravectys SA, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ViDAC Pharma Ltd., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd., H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..5), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..6), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..7), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..8), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..9), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..1), H2 2015
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..2), H2 2015

LIST OF FIGURES

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2015
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Altor BioScience Corporation
Amgen Inc.
Aprogen, Inc.
Arno Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Bayer AG
BeiGene(Beijing) Co.,Ltd
Bellicum Pharmaceuticals, Inc.
Biogen, Inc.
BioInvent International AB
Bionovis SA
Biothera, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cellectis S.A.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Cyclacel Pharmaceuticals, Inc.
Eli Lilly and Company
Emergent BioSolutions Inc.
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
Grupo Ferrer Internacional, S.A.
Hospira, Inc.
Hutchison MediPharma Limited
Hybrigenics S.A.
Igenica Biotherapeutics, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Inflection Biosciences Limited
Innate Pharma SA
Innovent Biologics, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
KAEL-GemVax Co., Ltd.
KaloBios Pharmaceuticals, Inc.
Kancera AB
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
LFB S.A.
Lymphocyte Activation Technologies, S.A.
Medicenna Therapeutics, Inc
MediGene AG
MedImmune, LLC
MENTRIK Biotech, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Molecular Templates Inc.
MorphoSys AG
NantKwest, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
Panacea Biotec Limited
PEP-Therapy SAS
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
Redx Pharma Plc
Respiratorius AB
Sandoz International GmbH
Sanofi
Selvita SA
Shanghai Henlius Biotech Co., Ltd.
Simcere Pharmaceutical Group
Sorrento Therapeutics, Inc.
Supratek Pharma Inc.
Targazyme, Inc.
TG Therapeutics, Inc.
The International Biotechnology Center (IBC) Generium
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
ViDAC Pharma Ltd.
Viralytics Ltd.
Zymeworks Inc.
Skip to top


Ask Your Question

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: